Doyle Brunson a living legend in the poker world once said; “The key to no-limit is to put a man to a decision for all his chips.” In the high stakes short-acting insulin market Lilly and Novo Nordisk and to some extent Sanofi currently have the best hands. However as everyone knows the best hand does not always win.
With billions at stake here we’re having a difficult time figuring out why the major insulin players are taking so long to bring Tyler to market. All three have connected pens, all three have apps which communicate or . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.